<DOC>
	<DOCNO>NCT00690820</DOCNO>
	<brief_summary>This study assess effect pancrelipase delay release 12,000 unit capsule fat nitrogen absorption subject 7 - 11 pancreatic exocrine insufficiency due Cystic Fibrosis .</brief_summary>
	<brief_title>Study Investigating Delayed-Release Pancrelipase Patients With Pancreatic Exocrine Insufficiency ( PEI ) Due Cystic Fibrosis ( CF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Confirmed CF diagnosis two positive chloride sweat test gene analysis Confirmed PEI historical Coefficient fat Absorption &lt; 70 % without supplementation current historical fecal elastase &lt; 50µg/stool ( within last 12 month ) Currently receive treatment commercially available pancreatic enzyme product stable dose 3 month Clinically stable condition without evidence acute respiratory disease acute condition Stable body weight agrees abstain sexual activity Ileus acute abdomen History fibrosing colonopathy , celiac disease , gastrectomy , Crohn´s disease small bowel surgery minor resection due meconium ileus without result malabsorption syndrome History distal ileal obstruction syndrome within 6 month enrollment Use immunosuppressive drug Any type malignancy involve digestive tract last 5 year Known infection HIV</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pancreatic Exocrine Insufficiency</keyword>
</DOC>